SARS-CoV-2 infection in cancer patients is associated with increased morbidity and mortality, their status defined as ‘clinically extremely vulnerable’ (CEV) with prioritisation for vaccine booster programs, including fifth doses [1]. For patients with Chronic myeloid leukemia (CML) there is uncertainty about their ability to mount a protective immune response against SARS-CoV-2 infection after COVID-19 vaccination. A retrospective study of 8665 CML patients has reported lower COVID-19 mortality than seen in other haematological malignancy.
Author list:
Affiliations:
- Department of Immunology and Inflammation, Imperial College London, London, UK
- Department of Infectious Disease, Imperial College London, London, UK
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- Imperial College NHS Healthcare Trust, London, UK
- Lung Division, Royal Brompton Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Authors:
Dragana Milojkovic1, Catherine J. Reynolds2, Diana Mūnoz Sandoval2, Franziska P. Pieper2, Siyi Liu2, Corinna Pade3, Joseph M. Gibbons3 Áine McKnight3, Sandra Loaiza4, Renuka Palanicawander4, Andrew J. Innes4, Simone Claudiani4, Jane F. Apperley1, Daniel M. Altmann1 & Rosemary J. Boyton2,5
